Global Chronic Refractory Cough Pipeline Insight Report 2019 -

DUBLIN--()--The "Chronic Refractory Cough Pipeline Insight, 2019" drug pipelines has been added to's offering.

Chronic Refractory Cough (CRC)-Pipeline Insight, 2019 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Chronic Refractory Cough pipeline landscape is provided which includes the disease overview and Chronic Refractory Cough treatment guidelines.

The assessment part of the report embraces, in depth Chronic Refractory Cough commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Chronic Refractory Cough collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Chronic Refractory Cough (CRC) Understanding

Chronic Refractory Cough (CRC) is defined as a cough lasting more than 8 weeks that persists despite guidelines based treatment which may be treated by different medical specialties: Pulmonology, Allergy and Immunology, Digestive Health and Otorhinolaryngology.

Patients with chronic cough experience impaired quality of life and interruption of activities of daily living. Chronic refractory cough often occurs after a viral infection and multiple factors contribute to CRC which is divided according to the conditions affecting the upper and lower respiratory tracts. Often the etiology can be multifactorial with more than one pathology present.

Chronic cough causes social isolation, anxiety, and depression. According to ACCP guidelines four categories of treatment that were supported by randomized controlled trials (RCTs) - nonpharmacologic therapies, inhaled corticosteroids, neuromodulatory therapies, and other therapies. The two main advances in treatment during the past decade have been nonpharmacologic approaches, such as speech pathology management, and the use of centrally acting neuromodulators.

Chronic Refractory Cough (CRC) Pipeline Development Activities

The report provides insights into different therapeutic candidates in discovery and preclinical, phase 1, phase 2, and phase 3 stage. Drugs under development as a monotherapy or combination therapy are also included. It also analyses key players involved in Chronic Refractory Cough targeted therapeutics development with respective active and inactive (dormant or discontinued) projects with the appropriate reasons if available. Chronic Refractory Cough pipeline report covers 10+ companies. Some of the key players include Merck (Gefapixant), NeRRe therapeutics (Orvepitant), BELLUS Health (BLU 5937) etc.

The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university web sites and industry-specific third party sources, etc.

Chronic Refractory Cough (CRC) Analytical Perspective

In-depth Chronic Refractory Cough Commercial Assessment of products

This report provides an in-depth Commercial Assessment of therapeutic drugs have been included which comprises of collaborations, Licensing, Acquisition -Deal Value Trends. The sub-segmentation is described in the report which includes Company-Company Collaborations (Licensing / Partnering), Company-Academia Collaborations, and Acquisition analysis in both Graphical and tabulated form.

Chronic Refractory Cough (CRC) Clinical Assessment of products

The report comprises of comparative clinical assessment of products by development stage, product type, route of administration, molecule type, and MOA type across this indication.

Key Topics Covered:

1. Report Introduction

2. Chronic Refractory Cough

2.1. Chronic Refractory Cough (CRC) Disease Overview

2.2. Chronic Refractory Cough (CRC) History

2.3. Chronic Refractory Cough (CRC) Symptoms

2.4. Chronic Refractory Cough (CRC) Causes

2.5. Chronic Refractory Cough (CRC) Pathophysiology

2.6. Chronic Refractory Cough (CRC) Diagnosis

2.6.1. Diagnostic Guidelines

3. Chronic Refractory Cough (CRC) Current Treatment Patterns

3.1. Treatment Guidelines

4. Chronic Refractory Cough (CRC)- Analytical Perspective

4.1. In-depth Commercial Assessment

4.1.1. Chronic Refractory Cough companies collaborations, Licensing, Acquisition -Deal Value Trends Assessment Summary

4.1.2. Chronic Refractory Cough Collaboration Deals Company-Company Collaborations (Licensing/Partnering) Analysis Chronic Refractory Cough Acquisition Analysis

4.2. Clinical Assessment of Pipeline Drugs

4.2.1. Assessment by Phase of Development

4.2.2. Assessment by Product Type (Mono/Combination)

4.2.3. Assessment by Route of Administration

4.2.4. Assessment by Molecule Type

4.2.5. Assessment by MOA

5. Chronic Refractory Cough (CRC) Pipeline Therapeutics

5.1. Late Stage Products (Phase-III)

5.1.1. Comparative Analysis

5.2. Mid Stage Products (Phase-II)

5.3. Early Stage Products (Phase-I)

5.4. Pre-clinical and Discovery Stage Products

5.5. Inactive Products

6. Chronic Refractory Cough (CRC) -Products Analysis

6.1. Product Profiles

6.1.1. Gefapixant- Merck

6.1.2. Orvepitant - NeRRe therapeutics

6.1.3. BLU 5937- BELLUS Health

7. Recent Technologies

8. Chronic Refractory Cough Key Companies

8.1. Attenua

8.2. NeRRe therapeutics

8.3. Axalbion

8.4. Cerecor

8.5. Patara Pharma

8.6. Shionogi

8.7. Glenmark Pharmaceuticals

8.8. Merck

8.9. AstraZeneca

8.10. Bayer

9. Chronic Refractory Cough Key Products

9.1. Bradanicline

9.2. Orvepitant

9.3. AX 8

9.4. Memantine

9.5. Sodium cromoglicate

9.6. S 600918

9.7. GRC 17536

9.8. Gefapixant

9.9. BLU 5937

9.10. BAY 1902607

9.11. BAY 1817080

10. Dormant and Discontinued Products

10.1. Dormant Products

10.1.1. Reasons for being dormant

10.2. Discontinued Products

10.2.1. Reasons for the discontinuation

11. Chronic Refractory Cough - Unmet Needs

12. Chronic Refractory Cough - Future Perspectives

13. Appendix

For more information about this drug pipelines report visit

Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900